大会主席：
Anthony M. Jevnikar, MD和 Roslyn B. Mannon, MD
大会组织者：
Yolanda T. Becker, MD, Anil Chandraker, MD和 Donald E. Hricik, MD
2008年3月13日，星期四
欢迎辞 6:30 PM
Donald E. Hricik, MD
AST Post-Graduate Education Director
开幕式 6:45 PM
主持人：Donald E. Hricik, MD
Life Years From Transplant (LYFT)
Alan Leichtman, MD
LYFT：有哪些益处？
Gabriel M. Danovitch, MD
讨论时间
欢迎会和赞助商颁奖典礼 7:45 PM--9:00 PM
2008年3月14日，星期五
高级讲座 8:00 AM–8:30 AM
主席: Anthony M. Jevnikar, MD 和 Roslyn B. Mannon, MD
移植候选名单的管理：专家进行的试验、遇到的困难以及问题
Robert S. Gaston, MD
普通会场I 8:30 AM–10:30 AM
移植候选名单上患者的免疫问题
主席：Anthony M. Jevnikar, MD 和Roslyn B. Mannon, MD
PRA和PRT：明确判断高风险患者 8:30 AM
Emilio Poggio, MD
肝脏、心脏、肺移植候选名单上患者的免疫风险 9:00 AM
Elaine Reed, PhD
一例高风险患者的案例：什么才是脱敏的“最佳”方案？ 9:30 AM
James M. Gloor, MD
对换或错配：如何选择？ 10:00 AM
Peter Nickerson, MD
休息 10:30 AM–11:00 AM
普通会场II 11:00 AM–1:00 PM
移植候选名单的实际问题
主席：Yolanda T. Becker, MD 和 Robert S. Gaston, MD
患者面临的心脏风险和“使患者活着”：应该选择创伤性还是非创伤性？ 11:00 AM
Connie L. Davis, MD
你是如何组织分配“良好器官”、“较好器官”和“最佳器官”的？ 11:30 AM
Yolanda T. Becker, MD
对非肾移植肾功能不全患者的管理 12:00 NN
Sandra Cockfield, MD
何时适合进行ABO血型不相容的移植？ 12:30 PM
C.F. Bryan, PhD
分会场I 2:00 PM–4:00 PM
小儿移植受体的管理：我们能够消除风险吗？
主席: Sharon M. Bartosh 和 William E. Harmon, MD
小儿免疫系统：个体化疗法的实质？ 2:00 PM
Lori J. West, MD, DPhil
小儿患者的依从性 2:30 PM
Sharon M. Bartosh, MD
充分监测药物疗法 3:00 PM
Michael Green, MD, MPH
移植后vs. 器官排斥的增长和发展：是否存在正确的疗法？ 3:30 PM
Mark R. Benfield, MD
分会场 II 2:00 PM–3:30 PM
肝移植高风险受体
主席：Rafik Mark Ghobrial, MD, PhD 和 Jeffrey S. Crippin, MD
肝移植候选名单的管理：应用ECD和DCD供肝 2:00 PM
John Fung, MD, PhD
肝移植和非肝移植受体病毒性肝炎的管理 2:30 PM
Jeffrey S. Crippin, MD
恶性肿瘤后的肝移植 3:00 PM
Rafik Mark Ghobrial, MD, PhD
海报论文、讨论、酒会 4:00 PM–6:00 PM
主持人：Donald E. Hricik, MD
包括以下临床研究、基础研究和移植领域的研究：
•进行移植
•对高风险患者的共识管理
•高风险移植的伦理学问题
•脱敏方法
•移植候选名单的管理
•分配机制变化所产生的影响（MELD/LYFT）
•有严重负面结果、未发表的临床试验
2008年3月15日，星期六
高级讲座 8:00 AM–8:30 AM
主席:Anthony M. Jevnikar, MD 和 Roslyn B. Mannon, MD
DCD、ECD和器官保存：炎症和缺血再灌注损伤的最新科技
Mark D. Okusa, MD
普通会场 III 8:30 AM–10:30 AM
管理高风险受体
主席：Allan Kirk, MD, PhD 和 Michelle Josephson, MD
我们真的需要进行“计划性活检”吗？ 8:30 AM
David Rush, MD
长期注射疗法：What's the "Point"? 9:00 AM
Flavio Vincenti, MD
高龄患者：更多还是更少的免疫抑制？ 9:30 AM
Anil Chandraker, MD
移植术后B细胞替换有哪些新进展：超出anti-CD20 10:00 AM
Milagros D. Samaniego, MD
休息 10:30 AM-11:00 AM
普通会场 IV 11:00 AM–1:00 PM
高风险捐赠者
主席：Flavio Vincenti, MD 和 Anil Chandraker, MD
器官保存和组织损伤：过去20年中我们取得了哪些进展？ 11:00 AM
Jerzy Kupiec-Weglinski, MD, PhD
一项最新研究成果：需要更多的捐赠者还是需要更好的捐赠者？ 11:30 AM
Alan Leichtman, MD
捐赠者的癌症风险：有哪些数据？ 12:00 NN
TBD
风险评估：伴肝炎、HTLV、和其他血清学阳性的捐赠者 12:30 PM
Emily A. Blumberg, MD
休息 1:00 PM–1:30 PM
普通会场 V 1:30 PM–3:00 PM
非肾脏移植患者的免疫情况
主席：Maryl R. Johnson, MD 和 Hugo R. Rosen, MD
肺移植患者免疫系统的管理 1:30 PM
Mark L. Barr, MD
脱敏心脏移植受体的管理 2:00 PM
Joren Madsen, MD, DPhil
排斥反应的管理：感染丙型肝炎的肝移植受体 2:30 PM
Hugo R. Rosen, MD
AST/NATCO联合研讨会 3:00 PM–5:00 PM
我是如何管理移植候选名单的
主持人: Anthony M. Jevnikar, MD, Roslyn B. Mannon, MD, 和 Jan Finn, RN, MSN
肾脏 3:00 PM–3:55 PM
Gabriel M. Danovitch, MD 3:00 PM
Cathy Garvey, RN, BA, CCTC 3:10 PM
Robert S. Gaston, MD 3:20 PM
Marian O'Rourke, RN, CCTC 3:30 PM
提问及解答 3:40 PM–3:55 PM
肝脏 3:55 PM–4:30 PM
John Fung, MD, PhD 3:55 PM
Barry Friedman, RN, BSN, MBA, CPTC 4:05 PM
提问及解答 4:15 PM–4:30 PM
心胸 4:30 PM–5:00 PM
Maryl R. Johnson, MD 4:30 PM
Lori Coleman, RN, CPTC 4:40 PM
提问及解答 4:50 PM–5:00 PM
2008年3月16日，星期日
普通会场 VI 8:30 AM–10:30 AM
移植中的风险和伦理学问题
主席: Donald Hricik, MD 和 Lori J. West, MD
移植旅游：我们该持怎样的立场？ 8:30 AM
Margaret Schwarze, MD
克服高风险移植的经济屏障 9:00 AM
Mark Schnitzler, PhD
对比美国和世界移植生存率：我们真的优秀吗？ 9:30 AM
John Gill, MD, MS
“有多少捐赠者？”需要向捐赠者支付费用吗？ 10:00 AM
Mark Fox, MD, PhD
休息 10:30 AM–11:00 AM
研讨会闭幕式，并公布下一任AST主席 11:00 AM
Flavio Vincenti, MD
AST 现任主席
AST未来展望：愿望与挑战 11:10 AM
Barbara Murphy, MD
AST新当选的主席
闭会 11:30 AM
AST Winter Symposium 2008 , "Emergence to Convergence: Management of High Risk Donors and Recipients"
Program Chairs:
Anthony M. Jevnikar, MD, and Roslyn B. Mannon, MD
Program Organizers:
Yolanda T. Becker, MD, Anil Chandraker, MD, and Donald E. Hricik, MD
THURSDAY, MARCH 13
Welcome Remarks 6:30 PM
Donald E. Hricik, MD
AST Post-Graduate Education Director
Opening Forum 6:45 PM
Moderator: Donald E. Hricik, MD
Life Years From Transplant (LYFT)
Alan Leichtman, MD
LYFT: What's the Benefit?
Gabriel M. Danovitch, MD
Open Discussion
Welcome Reception and Supporter Recognition Ceremony 7:45 PM–9:00 PM
FRIDAY, MARCH 14
State-of-the-Art Lecture 8:00 AM–8:30 AM
Chairs: Anthony M. Jevnikar, MD and Roslyn B. Mannon, MD
Managing Your Waiting List: Trials, Tribulations and Real Issues from the Experts
Robert S. Gaston, MD
General Session I 8:30 AM–10:30 AM
The Immunological Issues of the Waiting List
Chairs: Anthony M. Jevnikar, MD and Roslyn B. Mannon, MD
PRA and PRT: Clearly Identifying High Risk Patients 8:30 AM
Emilio Poggio, MD
Immune Risk in Liver, Heart and Lung Waiting Lists: Concerns, Caveats or Care? 9:00 AM
Elaine Reed, PhD
My High Risk Patient: What's the "Best" Protocol for Desensitizing? 9:30 AM
James M. Gloor, MD
Paired Exchange or Acceptable Mismatch: Which Road to Take? 10:00 AM
Peter Nickerson, MD
Break with networking and exhibits 10:30 AM–11:00 AM
General Session II 11:00 AM–1:00 PM
The Practical Issues of the Waiting List
Chairs: Yolanda T. Becker, MD and Robert S. Gaston, MD
Cardiac Risk and "Keeping Them Alive": Should We Be Invasive or Non-invasive? 11:00 AM
Connie L. Davis, MD
Assigning "Good," "Better" and "Best" Organs: How Do You Structure Your Program? 11:30 AM
Yolanda T. Becker, MD
Management of Non-renal Transplants with Renal Dysfunction 12:00 NN
Sandra Cockfield, MD
When Is It Easy to Be Compatible with ABO Incompatible? 12:30 PM
The A2 into B Story and Others
C.F. Bryan, PhD
Concurrent Session I 2:00 PM–4:00 PM
Managing Your Pediatric Transplant Recipients: Can We Eliminate the Risk?
Chairs: Sharon M. Bartosh and William E. Harmon, MD
The Pediatric Immune System: A Novel Entity for Tailoring Therapy? 2:00 PM
Lori J. West, MD, DPhil
Compliance in the Pediatric Patient 2:30 PM
Sharon M. Bartosh, MD
Monitoring Adequacy of Drug Therapy 3:00 PM
Michael Green, MD, MPH
Growth and Development after Transplantation vs. Organ Rejection: Is There a Correct Therapy? 3:30 PM
Mark R. Benfield, MD
Concurrent Session II 2:00 PM–3:30 PM
High Risk Liver Recipients
Chairs: Rafik Mark Ghobrial, MD, PhD and Jeffrey S. Crippin, MD
Managing the Liver Waiting List: Use of ECD and DCD Liver Grafts 2:00 PM
John Fung, MD, PhD
Management of Viral Hepatitis in Liver and Non-liver Transplant Recipients 2:30 PM
Jeffrey S. Crippin, MD
Liver Transplant after Malignancy 3:00 PM
Rafik Mark Ghobrial, MD, PhD
Poster Session, Discussion, and Wine and Cheese Reception 4:00 PM–6:00 PM
Moderator: Donald E. Hricik, MD
Clinical, basic, and translational studies in the categories of:
• Access to Transplantation
• Consensus Management of High-risk Patients
• Ethics of High Risk Transplantation
• Desensitization approaches
• Wait List Management
• Impact of Allocation Changes (MELD/LYFT)
• Unpublished Clinical Trials with Important Negative Findings
SATURDAY, MARCH 15
State-of-the-Art Lecture 8:00 AM–8:30 AM
Chairs: Anthony M. Jevnikar, MD and Roslyn B. Mannon, MD
DCD, ECD and Organ Preservation:What's the New Science in Inflammation and Ischemia-reperfusion Injury?
Mark D. Okusa, MD
General Session III 8:30 AM–10:30 AM
Managing the High Risk Recipient
Chairs: Allan Kirk, MD, PhD and Michelle Josephson, MD
Protocol Biopsies: Do We Really Need Them? 8:30 AM
David Rush, MD
Long-term Injection Therapy: What's the "Point"? 9:00 AM
Flavio Vincenti, MD
Older Patients: More or Less Immunosuppression? 9:30 AM
Anil Chandraker, MD
What's New in B-cell Elimination Post-transplant: Beyond Anti-CD20 10:00 AM
Milagros D. Samaniego, MD
Break with networking and exhibits 10:30 AM–11:00 AM
General Session IV 11:00 AM–1:00 PM
The High Risk Donor
Chairs: Flavio Vincenti, MD and Anil Chandraker, MD
Organ Preservation and Tissue Injury: How Far Have We Come in the Last 20 Years? 11:00 AM
Jerzy Kupiec-Weglinski, MD, PhD
More Donors or Better Donors? An Update on Outcomes 11:30 AM
Alan Leichtman, MD
Cancer Risk from Donors: What Are the Data? 12:00 NN
TBD
Donors with Hepatitis, HTLV and Other Positive Serologies: Assessing the Risk 12:30 PM
Emily A. Blumberg, MD
Break with networking and exhibits 1:00 PM–1:30 PM
General Session V 1:30 PM–3:00 PM
Immunity in Non-renal Transplants
Chairs: Maryl R. Johnson, MD and Hugo R. Rosen, MD
Management of the Immune System in Lung Transplantation 1:30 PM
Mark L. Barr, MD
Management of the Sensitized Cardiac Recipient 2:00 PM
Joren Madsen, MD, DPhil
Management of Rejection in the Hepatitis C-infected Liver Recipient 2:30 PM
Hugo R. Rosen, MD
AST/NATCO Joint Symposium 3:00 PM–5:00 PM
Waiting List Management: How I Do It
Moderators: Anthony M. Jevnikar, MD, Roslyn B. Mannon, MD, and Jan Finn, RN, MSN
Kidney 3:00 PM–3:55 PM
Gabriel M. Danovitch, MD 3:00 PM
Cathy Garvey, RN, BA, CCTC 3:10 PM
Robert S. Gaston, MD 3:20 PM
Marian O'Rourke, RN, CCTC 3:30 PM
Questions & Answers 3:40 PM–3:55 PM
Liver 3:55 PM–4:30 PM
John Fung, MD, PhD 3:55 PM
Barry Friedman, RN, BSN, MBA, CPTC 4:05 PM
Questions & Answers 4:15 PM–4:30 PM
Cardiothoracic 4:30 PM–5:00 PM
Maryl R. Johnson, MD 4:30 PM
Lori Coleman, RN, CPTC 4:40 PM
Questions & Answers 4:50 PM–5:00 PM
SUNDAY, MARCH 16
General Session VI 8:30 AM–10:30 AM
The Risks and Ethics in Transplantation
Chairs: Donald Hricik, MD and Lori J. West, MD
Transplant Tourism: Where Do We Stand and Where Should We Stand? 8:30 AM
Margaret Schwarze, MD
Overcoming the Economics of High Risk Transplantation 9:00 AM
Mark Schnitzler, PhD
Comparing US Survival to the World: Are We Really Excellent? 9:30 AM
John Gill, MD, MS
"How Much is that Donor in the Window?" Should We Pay for Our Donors Here? 10:00 AM
Mark Fox, MD, PhD
Break with networking and exhibits 10:30 AM–11:00
ASymposium Closing and Introduction of the Incoming AST President 11:00 AM
Flavio Vincenti, MD
AST President
The Future of AST: The Vision and the Challenges 11:10 AM
Barbara Murphy, MD
AST President-Elect
Adjourn 11:30 AM
[责任编辑:刘 聪]
|
